Physician profile
Barbara Lee Peterlin
NPI 1780664292
$608,590.01
in general payments reported to CMS, 2019-2025
12 companies · $103K in 2025
The $103K reported for 2025 was more than what 98% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $37K · 2020: $28K · 2021: $97K · 2022: $126K · 2023: $136K · 2024: $81K · 2025: $103K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $177K · Honoraria: $102K · Consulting Fee: $22K · Travel and Lodging: $11K · Food and Beverage: $6,321.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $177,290.00 |
| Honoraria | $102,250.00 |
| Consulting Fee | $22,307.27 |
| Travel and Lodging | $11,407.88 |
| Food and Beverage | $6,320.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $275,717.49 | 2021-2025 | |
| Lundbeck LLC | $165,009.78 | 2020-2025 | Vyepti |
| Amgen INC. | $75,216.96 | 2019-2022 | |
| Impel Pharmaceuticals INC. | $29,548.16 | 2022-2023 | Trudhesa |
| Biohaven Pharmaceutical Holding Company Ltd. | $27,939.70 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $26,187.48 | 2020-2021 | |
| Allergan, INC. | $8,811.78 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $77.64 | 2019-2021 | |
| Acorda Therapeutics, INC | $23.54 | 2019 | |
| Zyla Life Sciences, INC. | $22.28 | 2019 | |
| Lilly USA, LLC | $20.91 | 2019 | |
| Ucb, INC. | $14.29 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barbara Peterlin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.